Chinese health officials warn of mosquito-borne virus outbreak
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
4 hours ago
- CBC
Indigenous man endured racism in hospital: Manitoba officials
Health officials in northern Manitoba say Stephen Rockwell, who was Indigenous, faced racism while seeking health care in the final months of his life. His family says while the admission brings them some peace, it doesn't excuse what happened.
The Province
9 hours ago
- The Province
China tackles chikungunya virus outbreak with wide range of measures as thousands fall ill
Protocols have been adopted in a sign of China's determination to eliminate the outbreak and avoid public and international criticism Published Aug 06, 2025 • Last updated 9 hours ago • 2 minute read Residents walk past a residential entrance gate displaying a slogan urging mosquito control, in Guangzhou, south China's Guangdong Province, Aug. 6, 2025. The slogan reads "Let's work together to clear stagnant water and eliminate mosquito breeding." Photo by Chinatopix / AP TAIPEI, Taiwan — An outbreak of the chikungunya virus in China has prompted authorities to take preventive measures from mosquito nets and clouds of disinfectant, threatening fines for people who fail to disperse standing water, and even deploying drones to hunt down insect breeding grounds. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors More than 7,000 cases of the disease have been reported as of Wednesday, focused largely on the manufacturing hub of Foshan near Hong Kong. Numbers of new cases appear to be dropping slowly, according to authorities. Chikungunya is spread by mosquitoes and causes fever and joint pain, similar to dengue fever, with the young, older people and those with pre-existing medical conditions most at risk. Chinese state television has shown workers spraying clouds of disinfectant around city streets, residential areas, construction sites and other areas where people may come into contact with virus-bearing mosquitos that are born in standing water. Workers sprayed some places before entering office buildings, a throwback to China's controversial hardline tactics used to battle the COVID-19 virus. Essential reading for hockey fans who eat, sleep, Canucks, repeat. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. People who do not empty bottles, flower pots or other outdoor receptacles can be subject to fines of up to 10,000 yuan ($US1,400) and have their electricity cut off. The U.S. has issued a travel advisory telling citizens not to visit China's Guangdong province, the location of Donguan and several other business hubs, along with countries such as Bolivia and island nations in the Indian Ocean. Brazil is among the other countries hit hard by the virus. The crisis in China has been worsened by heavy rains and high temperatures, which are generally common in tropical areas but came on unusually strong this year. China has become adept at coercive measures that many nations consider over-the-top since the deadly 2003 SARS outbreak. This time, patients are being forced to stay in hospital in Foshan for a minimum of one week, and authorities briefly enforced a two-week home quarantine, which was dropped since the disease cannot be transmitted between people. This advertisement has not loaded yet, but your article continues below. Reports also have emerged of attempts to stop the virus spread with fish that eat mosquito larvae, and even larger mosquitos to eat the insects carrying the virus. Meetings have been held and protocols adopted at the national level in a sign of China's determination to eliminate the outbreak and avoid public and international criticism. Read More Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our newsletters here. Vancouver Whitecaps Vancouver Canucks Local News Sports Crime
Globe and Mail
13 hours ago
- Globe and Mail
Chronic Lymphocytic Leukemia Pipeline Outlook Report 2025: Key 55+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Chronic Lymphocytic Leukemia Pipeline Insight 2025' report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline landscape. It covers the Chronic Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Chronic Lymphocytic Leukemia Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Chronic Lymphocytic Leukemia Pipeline Outlook Report In July 2025, AstraZeneca announced a Phase IV study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally [po], twice daily [bd]) compared to investigator's choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. All patients will have cardiac impairment as defined by LVEF of < 50%. In July 2025, BeiGene announced a study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax. In July 2025, AbbVie conducted a study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 120 adult participants with CLL who are being treated with venetoclax will be enrolled in the study in approximately 80 sites worldwide. DelveInsight's Chronic Lymphocytic Leukemia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Chronic Lymphocytic Leukemia treatment. The leading Chronic Lymphocytic Leukemia Companies such as Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Promising Chronic Lymphocytic Leukemia Therapies such as Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others. Discover how the Chronic Lymphocytic Leukemia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Chronic Lymphocytic Leukemia Clinical Trials and Studies Chronic Lymphocytic Leukemia Emerging Drugs Profile Pirtobrutinib: Loxo Oncology Pirtobrutinib is an investigational, oral, highly-selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor, signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. The drug is currently being evaluated in Phase III stage of development for the treatment of chronic lymphocytic leukemia. Cirmtuzumab: Oncternal Therapeutics Cirmtuzumab is a first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1). ROR1 is a type 1 transmembrane protein, essential for fetal development that is expressed on the plasma membrane with an extracellular domain that is essential for ligand binding and signal transduction. Cirmtuzumab binds to many different types of cancer cells but does not recognize most normal adult tissues. Cirmtuzumab was developed at the University of California in San Diego based on the pioneering scientific research of Thomas Kipps, MD, Ph.D., and his colleagues at the Moores Cancer Center. Oncternal holds an exclusive worldwide license to develop and commercialize antibodies recognizing ROR1. The development of cirmtuzumab has been supported by the California Institute for Regenerative Medicine (CIRM), in recognition of the role of ROR1 in conferring stem cell-like properties to the cancer cells that express it. A Phase II clinical trial is evaluating Cirmtuzumab to treat CLL. MS-553: MingSight Pharmaceuticals MS-553 is a potent, highly selective, oral, non-covalent inhibitor of PKCβ, a signaling molecule immediately downstream of BTK and PLCγ2 in the B-cell receptor (BCR) pathway. As PKCβ is downstream of both BTK and PLCγ2, it has the potential to treat acquired BTK resistance mutations in either protein, a feature absent from many second-generation BTK inhibitors. In the preliminary results, MS-553 was generally well tolerated, with initial anti-tumor activity seen in the heavily pretreated population. Potent to full inhibition of PKCβ signaling over 24 hours of exposure has been demonstrated. Additional dosing of patients will be completed to further assess MS-553 efficacy in patients with acquired resistance mutations in BTK and PLCG2. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of CLL. NX-2127: Nurix Therapeutics NX-2127 is an oral small molecule that combines the activity of a targeted BTK degrader with the cereblon immunomodulatory activity of an IKZF degrader. Cereblon immunomodulatory drugs that induce degradation are IKZF1 and IKZF3. Preclinical data support the activity of NX-2127 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to FDA-approved agents. Studies in non-human primates confirm potent BTK degradation with once-daily oral dosing. NX-2127 is being tested in an ongoing Phase I trial for patients with chronic lymphocytic leukemia who have failed prior treatments. NX-5948: Nurix Therapeutics NX-5948 is an oral small molecule degrader of BTK. Preclinical data support the activity of NX-5948 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to leading FDA approved agents. NX-5948 lacks cereblon immunomodulatory activity and has demonstrated the ability to cross the blood-brain barrier in animal models. NX-5948 has also demonstrated activity in animal models of autoimmune disease. The drug is currently being evaluated in the Phase I stage of development for the treatment of chronic lymphocytic leukemia. The Chronic Lymphocytic Leukemia Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Lymphocytic Leukemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Lymphocytic Leukemia Treatment. Chronic Lymphocytic Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chronic Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Lymphocytic Leukemia market Explore groundbreaking therapies and clinical trials in the Chronic Lymphocytic Leukemia Pipeline. Access DelveInsight's detailed report now! @ New Chronic Lymphocytic Leukemia Drugs Chronic Lymphocytic Leukemia Companies Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Chronic lymphocytic leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Chronic Lymphocytic Leukemia Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Chronic Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives Scope of the Chronic Lymphocytic Leukemia Pipeline Report Coverage- Global Chronic Lymphocytic Leukemia Companies- Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Chronic Lymphocytic Leukemia Therapies- Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others. Chronic Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chronic Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Chronic Lymphocytic Leukemia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Chronic Lymphocytic Leukemia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Chronic lymphocytic leukemia: Overview Pipeline Therapeutics Therapeutic Assessment Chronic lymphocytic leukemia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Pirtobrutinib: Loxo Oncology Drug profiles in the detailed report….. Mid Stage Products (Phase II) Cirmtuzumab: Oncternal Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) NX-2127: Nurix Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Chronic lymphocytic leukemia Key Companies Chronic lymphocytic leukemia Key Products Chronic lymphocytic leukemia- Unmet Needs Chronic lymphocytic leukemia- Market Drivers and Barriers Chronic lymphocytic leukemia- Future Perspectives and Conclusion Chronic lymphocytic leukemia Analyst Views Chronic lymphocytic leukemia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
